Leanne M Ward

List of Publications by Year
in descending order

118 papers	9,940 citations	50276 46 h-index	36028 97 g-index
123 all docs	123 docs citations	123 times ranked	7843 citing authors

#	Article	IF	Citations
1	Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nature Genetics, 2006, 38, 1310-1315.	21.4	1,063
2	Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurology, The, 2018, 17, 251-267.	10.2	767
3	Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurology, The, 2018, 17, 347-361.	10.2	668
4	Dual Energy X-ray Absorptiometry Interpretation and Reporting in Children and Adolescents: The 2007 ISCD Pediatric Official Positions. Journal of Clinical Densitometry, 2008, 11, 43-58.	1.2	480
5	Type V Osteogenesis Imperfecta: A New Form of Brittle Bone Disease. Journal of Bone and Mineral Research, 2000, 15, 1650-1658.	2.8	440
6	Osteogenesis Imperfecta Type VI: A Form of Brittle Bone Disease with a Mineralization Defect. Journal of Bone and Mineral Research, 2002, 17, 30-38.	2.8	403
7	Deletion of the NESP55 differentially methylated region causes loss of maternal GNAS imprints and pseudohypoparathyroidism type Ib. Nature Genetics, 2005, 37, 25-27.	21.4	321
8	Vitamin D-deficiency rickets among children in Canada. Cmaj, 2007, 177, 161-166.	2.0	278
9	Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurology, The, 2018, 17, 445-455.	10.2	268
10	Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone, 2002, 31, 12-18.	2.9	241
11	Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet, The, 2019, 393, 2416-2427.	13.7	229
12	Sensitivity of Fibroblast Growth Factor 23 Measurements in Tumor-Induced Osteomalacia. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2055-2061.	3.6	214
13	Clinical Review: Bisphosphonate Use in Childhood Osteoporosis. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 400-409.	3.6	206
14	Advanced Vertebral Fracture Among Newly Diagnosed Children With Acute Lymphoblastic Leukemia: Results of the Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) Research Program. Journal of Bone and Mineral Research, 2009, 24, 1326-1334.	2.8	188
15	Alendronate for the Treatment of Pediatric Osteogenesis Imperfecta: A Randomized Placebo-Controlled Study. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 355-364.	3.6	184
16	Diagnosis and Management of Osteopetrosis: Consensus Guidelines From the Osteopetrosis Working Group. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3111-3123.	3.6	170
17	Global Consensus Recommendations on Prevention and Management of Nutritional Rickets. Hormone Research in Paediatrics, 2016, 85, 83-106.	1.8	158
18	Rickets. Nature Reviews Disease Primers, 2017, 3, 17101.	30.5	131

#	Article	IF	Citations
19	Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders. Arthritis Care and Research, 2010, 62, 516-526.	3.4	124
20	Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: A national observational study. Arthritis Care and Research, 2012, 64, 122-131.	3.4	121
21	High Incidence of Vertebral Fractures in Children With Acute Lymphoblastic Leukemia 12 Months After the Initiation of Therapy. Journal of Clinical Oncology, 2012, 30, 2760-2767.	1.6	120
22	Bone Health in Children and Adolescents With Chronic Diseases That May Affect the Skeleton: The 2013 ISCD Pediatric Official Positions. Journal of Clinical Densitometry, 2014, 17, 281-294.	1.2	119
23	The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy. Osteoporosis International, 2012, 23, 2703-2711.	3.1	115
24	The management of osteoporosis in children. Osteoporosis International, 2016, 27, 2147-2179.	3.1	113
25	Incidence of vitamin D deficiency rickets among Australian children: an Australian Paediatric Surveillance Unit study. Medical Journal of Australia, 2012, 196, 466-468.	1.7	104
26	Maternal and Fetal Outcome After Long-Term Pamidronate Treatment Before Conception: A Report of Two Cases. Journal of Bone and Mineral Research, 2004, 19, 1742-1745.	2.8	97
27	Efficacy of food fortification on serum 25-hydroxyvitamin D concentrations: systematic review. American Journal of Clinical Nutrition, 2008, 88, 1528-1534.	4.7	96
28	Incident Vertebral Fractures and Risk Factors in the First Three Years Following Glucocorticoid Initiation Among Pediatric Patients With Rheumatic Disorders. Journal of Bone and Mineral Research, 2015, 30, 1667-1675.	2.8	94
29	Incident Vertebral Fractures in Children With Leukemia During the Four Years Following Diagnosis. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3408-3417.	3.6	93
30	Bisphosphonate therapy for children and adolescents with secondary osteoporosis. The Cochrane Library, 2010, 2010, CD005324.	2.8	87
31	The Utility of DXA Assessment at the Forearm, Proximal Femur, and Lateral Distal Femur, and Vertebral Fracture Assessment in the Pediatric Population: 2019 ISCD Official Position. Journal of Clinical Densitometry, 2019, 22, 567-589.	1.2	83
32	Bone Morbidity and Recovery in Children With Acute Lymphoblastic Leukemia: Results of a Six-Year Prospective Cohort Study. Journal of Bone and Mineral Research, 2018, 33, 1435-1443.	2.8	79
33	Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. Pharmacological Research, 2018, 136, 140-150.	7.1	69
34	Osteogenesis imperfecta type VII maps to the short arm of chromosome 3. Bone, 2002, 31, 19-25.	2.9	66
35	Resolution of severe, adolescent-onset hypophosphatemic rickets following resection of an FGF-23-producing tumour of the distal ulna. Bone, 2004, 34, 905-911.	2.9	66
36	Molecular analysis of DMP1 mutants causing autosomal recessive hypophosphatemic rickets. Bone, 2009, 44, 287-294.	2.9	66

#	Article	IF	Citations
37	Iliac bone histomorphometry in children with newly diagnosed inflammatory bowel disease. Osteoporosis International, 2010, 21, 331-337.	3.1	66
38	A Contemporary View of the Definition and Diagnosis of Osteoporosis in Children and Adolescents. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2088-e2097.	3.6	64
39	The time to and determinants of first fractures in boys with Duchenne muscular dystrophy. Osteoporosis International, 2017, 28, 597-608.	3.1	59
40	Single-Dose Pharmacokinetics and Tolerability of Alendronate 35- and 70-Milligram Tablets in Children and Adolescents with Osteogenesis Imperfecta Type I. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4051-4056.	3.6	54
41	Skeletal findings in children recently initiating glucocorticoids for the treatment of nephrotic syndrome. Osteoporosis International, 2012, 23, 751-760.	3.1	54
42	The Choice of Normative Pediatric Reference Database Changes Spine Bone Mineral Density Z-Scores But Not the Relationship Between Bone Mineral Density and Prevalent Vertebral Fractures. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1018-1027.	3.6	51
43	Unexpected widespread hypophosphatemia and bone disease associated with elemental formula use in infants and children. Bone, 2017, 97, 287-292.	2.9	50
44	Common normal variants of pediatric vertebral development that mimic fractures: a pictorial review from a national longitudinal bone health study. Pediatric Radiology, 2015, 45, 593-605.	2.0	49
45	Effect of Calcium and Vitamin D Supplementation on Bone Mineral Density in Children With Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2007, 45, 538-545.	1.8	48
46	Anatomical distribution of vertebral fractures: comparison of pediatric and adult spines. Osteoporosis International, 2012, 23, 1999-2008.	3.1	48
47	Bone Health and Osteoporosis Management of the Patient With Duchenne Muscular Dystrophy. Pediatrics, 2018, 142, S34-S42.	2.1	48
48	Skeletal findings in the first 12Âmonths following initiation of glucocorticoid therapy for pediatric nephrotic syndrome. Osteoporosis International, 2014, 25, 627-637.	3.1	45
49	Clinical Guidelines for Management of Bone Health in Rett Syndrome Based on Expert Consensus and Available Evidence. PLoS ONE, 2016, 11, e0146824.	2.5	45
50	Vitamin D deficiency in the 21st century: a persistent problem among Canadian infants and mothers. Cmaj, 2005, 172, 769-770.	2.0	44
51	Incidence and characteristics of vitamin D deficiency rickets in New Zealand children: a New Zealand Paediatric Surveillance Unit study. Australian and New Zealand Journal of Public Health, 2015, 39, 380-383.	1.8	40
52	Osteoporosis due to Glucocorticoid Use in Children with Chronic Illness. Hormone Research in Paediatrics, 2005, 64, 209-221.	1.8	39
53	Growth and weight gain in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort. Pediatric Rheumatology, 2017, 15, 68.	2.1	39
54	Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3241-e3253.	3.6	36

#	Article	IF	Citations
55	Skeletal Morbidity in Children and Adolescents during and following Cancer Therapy. Hormone Research in Paediatrics, 2019, 91, 137-151.	1.8	35
56	Histomorphometry and Bone Matrix Mineralization Before and After Bisphosphonate Treatment in Boys With Duchenne Muscular Dystrophy: A Paired Transiliac Biopsy Study. Journal of Bone and Mineral Research, 2016, 31, 1060-1069.	2.8	34
57	Osteogenesis Imperfecta Type I Caused by COL1A1 Deletions. Calcified Tissue International, 2016, 98, 76-84.	3.1	32
58	Musculoskeletal health in newly diagnosed children with Crohnâ€™s disease. Osteoporosis International, 2017, 28, 3169-3177.	3.1	32
59	Glucocorticoid-Induced Osteoporosis: Why Kids Are Different. Frontiers in Endocrinology, 2020, 11, 576.	3.5	32
60	Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy. JAMA Network Open, 2022, 5, e2144178.	5.9	31
61	DMP1 C-terminal mutant mice recapture the human ARHR tooth phenotype. Journal of Bone and Mineral Research, 2010, 25, 2155-2164.	2.8	29
62	Vertebral fractures despite normal spine bone mineral density in a boy with nephrotic syndrome. Pediatric Nephrology, 2011, 26, 139-142.	1.7	29
63	Molecular diagnosis in children with fractures but no extraskeletal signs of osteogenesis imperfecta. Osteoporosis International, 2017, 28, 2095-2101.	3.1	29
64	Bone mineral density surveillance for childhood, adolescent, and young adult cancer survivors: evidence-based recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Diabetes and Endocrinology,the, 2021, 9, 622-637.	11.4	29
65	Osteosclerosis in two brothers with autosomal dominant pseudohypoparathyroidism type 1b: bone histomorphometric analysis. European Journal of Endocrinology, 2011, 164, 295-301.	3.7	28
66	The impact of underlying disease on fracture risk and bone mineral density in children with rheumatic disorders: A review of current literature. Seminars in Arthritis and Rheumatism, 2016, 46, 49-63.	3.4	28
67	A Novel A10E Homozygous Mutation in the HSD3B2 Gene Causing Severe Salt-Wasting 3Â-Hydroxysteroid Dehydrogenase Deficiency in 46,XX and 46,XY French-Canadians: Evaluation of Gonadal Function after Puberty. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1968-1974.	3.6	27
68	The Spectrum of Pediatric Osteoporosis. , 2003, , 401-442.		26
69	Obesity and Endocrine Management of the Patient With Duchenne Muscular Dystrophy. Pediatrics, 2018, 142, S43-S52.	2.1	26
70	Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia. Calcified Tissue International, 2021, 108, 622-633.	3.1	26
71	Observer agreement in pediatric semiquantitative vertebral fracture diagnosis. Pediatric Radiology, 2014, 44, 457-466.	2.0	24
72	Growth, pubertal development, and skeletal health in boys with Duchenne Muscular Dystrophy. Current Opinion in Endocrinology, Diabetes and Obesity, 2019, 26, 39-48.	2.3	23

#	Article	IF	Citations
73	Targeting the Muscle-Bone Unit: Filling Two Needs with One Deed in the Treatment of Duchenne Muscular Dystrophy. Current Osteoporosis Reports, 2018, 16, 541-553.	3.6	22
74	Yunis-VarÃ³n syndrome caused by biallelic VAC14 mutations. European Journal of Human Genetics, 2017, 25, 1049-1054.	2.8	21
75	Anabolic Therapy for the Treatment of Osteoporosis in Childhood. Current Osteoporosis Reports, 2018, 16, 269-276.	3.6	21
76	Genetic changes in the RNA components of RNase MRP and RNase P in Schmid metaphyseal chondrodysplasia. Journal of Medical Genetics, 2003, 40, 741-746.	3.2	20
77	Glucocorticoidâ€related changes in body mass index among children and adolescents with rheumatic diseases. Arthritis Care and Research, 2013, 65, 113-121.	3.4	18
78	Report of the CCFA Pediatric Bone, Growth and Muscle Health Workshop, New York City, November 11â€“12, 2011, With Updates. Inflammatory Bowel Diseases, 2013, 19, 2919-2926.	1.9	18
79	New developments in the management of achondroplasia. Wiener Medizinische Wochenschrift, 2020, 170, 104-111.	1.1	18
80	The Spectrum of Recovery From Fractureâ€Induced Vertebral Deformity in Pediatric Leukemia. Pediatric Blood and Cancer, 2016, 63, 1107-1110.	1.5	17
81	The Radiology of Vertebral Fractures in Childhood Osteoporosis Related to Glucocorticoid Administration. Journal of Clinical Densitometry, 2016, 19, 81-88.	1.2	16
82	Use of bisphosphonates in the treatment of pediatric osteoporosis. International Journal of Clinical Rheumatology, 2009, 4, 657-672.	0.3	15
83	A case of moyamoya syndrome and hemoglobin E/betaâ€thalassemia. Pediatric Blood and Cancer, 2009, 52, 422-424.	1.5	15
84	Vitamin D supplementation for children with cancer: A systematic review and consensus recommendations. Cancer Medicine, 2021, 10, 4177-4194.	2.8	13
85	Zoledronic Acid vs Placebo in Pediatric Glucocorticoid-Induced Osteoporosis: A Randomized, Double-Blind, Phase 3 Trial. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e5222-e5235.	3.6	13
86	Bioavailability and Short-Term Tolerability of Alendronate in Glucocorticoid-Treated Children. Clinical Therapeutics, 2011, 33, 1516-1523.	2.5	11
87	Infantile Malignant Osteopetrosis. Journal of Pediatrics, 2013, 163, 1230-1230.e1.	1.8	11
88	Oral bisphosphonates for paediatric osteogenesis imperfecta?. Lancet, The, 2013, 382, 1388-1389.	13.7	11
89	Increased bone matrix mineralization in treatment-naÃ¯ve children with inflammatory bowel disease. Bone, 2017, 105, 50-56.	2.9	11
90	Local Tumor Recurrence and Escape from Suppression of Bone Resorption With Denosumab Treatment in Two Adolescents With Giant Cell Tumors of Bone. JBMR Plus, 2019, 3, e10196.	2.7	11

#	Article	IF	Citations
91	Impact of Vertebral Fractures and Glucocorticoid Exposure on Height Deficits in Children During Treatment of Leukemia. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 213-222.	3.6	11
92	Dominant osteogenesis imperfecta with low bone turnover caused by a heterozygous SP7 variant. Bone, 2022, 160, 116400.	2.9	10
93	An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries. Orphanet Journal of Rare Diseases, 2022, 17, 113.	2.7	9
94	The Accuracy of Prevalent Vertebral Fracture Detection in Children Using Targeted Caseâ€Finding Approaches. Journal of Bone and Mineral Research, 2020, 35, 460-468.	2.8	8
95	Part I: Which Child with a Chronic Disease Needs Bone Health Monitoring?. Current Osteoporosis Reports, 2021, 19, 278-288.	3.6	8
96	Part 2: When Should Bisphosphonates Be Used in Children with Chronic Illness Osteoporosis?. Current Osteoporosis Reports, 2021, 19, 289-297.	3.6	8
97	Nucleus-targeted Dmp1 transgene fails to rescue dental defects in Dmp1 null mice. International Journal of Oral Science, 2014, 6, 133-141.	8.6	7
98	A21: Physical Activity in Children with Juvenile Idiopathic Arthritis (JIA): The LEAP (Linking Exercise,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 S33-S34.	5.6	7
99	The Bone Phenotype and Pain Response to Pamidronate in Tyrosine Kinase Inhibitorâ€“Treated Chronic Myelogenous Leukemia. Journal of the Endocrine Society, 2019, 3, 857-864.	0.2	6
100	Long-Term Follow-up of Hypophosphatemic Bone Disease Associated With Elemental Formula Use: Sustained Correction of Bone Disease After Formula Change or Phosphate Supplementation. Clinical Pediatrics, 2020, 59, 1080-1085.	0.8	6
101	Advances in the Bone Health Assessment of Children. Endocrinology and Metabolism Clinics of North America, 2020, 49, 613-636.	3.2	6
102	A154: Glucocorticoid Therapy and the Risk of Incident Vertebral Fracture in Children with Rheumatic Disorders. Arthritis and Rheumatology, 2014, 66, S199-S200.	5.6	5
103	A Validated Risk Prediction Model for Bone Fragility in Children With Acute Lymphoblastic Leukemia. Journal of Bone and Mineral Research, 2020, 36, 2290-2299.	2.8	5
104	Osteoporotic Fractures and Vertebral Body Reshaping in Children With Glucocorticoid-Treated Rheumatic Disorders. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e5195-e5207.	3.6	4
105	Pigment epithelium-derived factor (PEDF) normalizes matrix defects in iPSCs derived from Osteogenesis imperfecta Type VI. Rare Diseases (Austin, Tex), 2016, 4, e1212150.	1.8	3
106	Osteoporosis: Diagnosis and Management. , 2018, , 525-565.		3
107	An Introduction to the Duchenne Muscular Dystrophy Care Considerations. Pediatrics, 2018, 142, S1-S4.	2.1	3
108	Disorders of Calcium, Phosphorus, and Bone Metabolism During Fetal and Neonatal Development. , 2020, , 755-782.		3

#	Article	IF	Citations
109	The Accuracy of Incident Vertebral Fracture Detection in Children Using Targeted Case-Finding Approaches. Journal of Bone and Mineral Research, 2020, 36, 1255-1268.	2.8	3
110	Renal phosphate--wasting disorders in childhood. Pediatric Endocrinology Reviews, 2005, 2 Suppl 3, 342-50.	1.2	3
111	Preventing symptomatic vitamin D deficiency and rickets among Indigenous infants and children in Canada. Paediatrics and Child Health, 2022, 27, 127-127.	0.6	3
112	The development of bone mineral lateralization in the arms. Osteoporosis International, 2013, 24, 999-1006.	3.1	2
113	Severe vitamin D deficiency: A persistent yet preventable problem among Canadian youth. Paediatrics and Child Health, 2017, 22, 43-44.	0.6	2
114	Beyond Bone Mineral Density: The Impact of Childhood Cancer and Its Treatment on Bone Structure and Strength. Frontiers of Hormone Research, 2021, 54, 1-22.	1.0	1
115	The Effects of Physical Activity on Physeal and Skeletal Development. JBJS Reviews, 2021, 9, .	2.0	1
116	FGF23 and hypophosphatemia: Clinical aspects. Bone, 2009, 45, S49-S50.	2.9	0
117	Impaired muscle function and tibial bone deficits in children with CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 2009, 15, S19.	1.9	0
118	La prÃ©vention de la carence en vitamine D symptomatique et du rachitisme chez les nourrissons et les enfants autochtones du Canada. Paediatrics and Child Health, 2022, 27, 128-128.	0.6	0